Evidence map›Paper›PMID 40369023›Full record

ArticleNPJ precision oncology2025

Benchmarking large language models GPT-4o, llama 3.1, and qwen 2.5 for cancer genetic variant classification.

Kuan-Hsun Lin, Tzu-Hang Kao, Lei-Chi Wang, Chen-Tsung Kuo, Paul Chih-Hsueh Chen, Yuan-Chia Chu, Yi-Chen Yeh

Abstract read
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. ChatGPT in precision medicine.APL bioengineering · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kuan-Hsun LinDepartment of Information Management, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Tzu-Hang KaoDepartment of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Lei-Chi WangDepartment of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Chen-Tsung KuoDepartment of Information Management, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Paul Chih-Hsueh ChenDepartment of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Yuan-Chia ChuDepartment of Information Management, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. xd.yuanchia@gmail.com.
Yi-Chen YehDepartment of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. lordaaa@gmail.com.

Funding

National Science and Technology Council NSTC 112-2320-B-075-004-MY3Taipei Veterans General Hospital, Taiwan V114E-004-3
6 · The paper itself

Abstract

Classifying cancer genetic variants based on clinical actionability is crucial yet challenging in precision oncology. Large language models (LLMs) offer potential solutions, but their performance remains underexplored. This study evaluates GPT-4o, Llama 3.1, and Qwen 2.5 in classifying genetic variants from the OncoKB and CIViC databases, as well as a real-world dataset derived from FoundationOne CDx reports. GPT-4o achieved the highest accuracy (0.7318) in distinguishing clinically relevant variants from variants of unknown clinical significance (VUS), outperforming Qwen 2.5 (0.5731) and Llama 3.1 (0.4976). LLMs demonstrated better concordance with expert annotations for variants with strong clinical evidence but exhibited greater inconsistencies for those with weaker evidence. All three models showed a tendency to assign variants to higher evidence levels, suggesting a propensity for overclassification. Prompt engineering significantly improved accuracy, while retrieval-augmented generation (RAG) further enhanced performance. Stability analysis across 100 iterations revealed greater consistency with the CIViC system than with OncoKB. These findings highlight the promise of LLMs in cancer genetic variant classification while underscoring the need for further optimization to improve accuracy, consistency, and clinical applicability.

Identifiers

PMID40369023
PMCPMC12078457

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.